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Surgery for symptomatic spinal metastases is effective at prolonging ambulation and life, 32 
but may appear costly at first glance. We have studied the difference between the cost of surgery 33 
and reimbursement received, as well as the cost-effectiveness of surgery in a UK tertiary referral 34 
spinal center. 35 
Methods 36 
A cost versus reimbursement and cost-utility analysis was performed in a prospective 37 
cohort of patients admitted for surgical treatment of spinal metastases. Outcome measures were 38 
health-related quality of life using the EuroQol EQ-5D-3L, Frankel score, quality-adjusted life 39 
years (QALYs), treatment and reimbursement costs. 40 
Results 41 
130 consecutive patients were prospectively recruited, of whom 92 had information 42 
available for cost and reimbursement comparison, and 100 had information to complete cost 43 
utility analysis. Median cost of hospital treatment per patient was £20,752; median 44 
reimbursement received was £18,291, with a median shortfall of £1,967. Surgery in addition to 45 
radiotherapy over a lifetime horizon was both more effective and less costly than radiotherapy 46 
alone, and therefore was found to be cost-effective. 47 
Conclusion 48 
Our results demonstrate that reimbursement to hospitals for surgical management of 49 
symptomatic spinal metastases in the UK is broadly in line with costs, and that there was an 50 
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overall saving as a result of community care costs being mitigated by patients walking for longer, 51 
which is within the expected National Health Service (NHS) threshold. Surgery for metastatic 52 
spinal tumors is effective and good value for money. 53 
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 59 
INTRODUCTION 60 
Spinal metastases occur in up to 75% of the most common cancers, including breast, 61 
prostate and lung cancer,1,2 of which 26% may develop into skeletal related events including 62 
pathological fracture and metastatic spinal cord compression (MSCC).3 In the UK, the National 63 
Institute for Health and Care Excellence (NICE) have produced guidelines that promote surgical 64 
management in around 70% of patients presenting with symptoms of MSCC.4,5 These guidelines 65 
are supported by Patchell et al (2005), who demonstrated a higher percentage of people able to 66 
mobilize, greater longevity of ambulation and better survival following surgical management in 67 
conjunction with radiotherapy compared to radiotherapy alone as primary treatment.6 Despite 68 
surgery, MSCC has a significant impact on quality of life and survival,7 and in tandem there are 69 
significant hospital costs associated with the surgical management of symptomatic spinal 70 
metastases, which we have previously reported as averaging £16,885 per patient,8 and when 71 
combined with out of hospital costs may be as high as €87,814.9 Providing good value 72 
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healthcare, which is both high quality and affordable is vital to the sustainability of the NHS and 73 
other publically funded health care systems.10 In today’s tough economic climate there is an 74 
emerging body of literature analyzing the cost-effectiveness of medical interventions to inform 75 
process changes that promote efficiency.11 Clinicians are in the optimal position to develop and 76 
deliver changes to practice, maintaining the focus on high quality patient care. 77 
Different financial metrics are available to assist with analysis. We have previously 78 
reported the average in-hospital cost of surgically treating symptomatic spinal metastases in one 79 
UK center.8 The difference between this and the reimbursement rate that the hospital receives 80 
from the NHS centrally is important at local and national levels; this has not yet been determined 81 
in patients with symptomatic spinal metastases. In other conditions, including hip and knee 82 
revision surgery, there is a possible shortfall in reimbursement of between £861 and £4566 per 83 
patient,12,13 which was suggested to be largely associated with a more complex patient case-mix 84 
than the NHS average in the hospitals studied, with patients requiring more expensive or longer 85 
treatment despite receiving the same, nationally-averaged, reimbursement tariff for that patient 86 
group. This shortfall requires the departments in question to implement more efficient pathways, 87 
or negotiate local variations to the tariff. As an additional incentive for some departments, 88 
several tariffs are now reimbursed based on the cost of evidence-based, efficient, patient 89 
pathways, rather than national average cost, and future tariffs may be split between health and 90 
social care systems.14 91 
At a national level, recommendations for healthcare service provision are based on cost 92 
utility analysis, balancing cost of treatment with quality and length of life gained following 93 
treatment, measured in quality adjusted life years (QALYs).15 Recommendations by the National 94 
Institute for Health and Care Excellence (NICE) have implied an upper limit of £30,000/QALY 95 
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for NHS funded treatments,15,16 although there is considerable debate about the appropriateness 96 
of this threshold,16,17 and a suggestion that populations may be willing to pay more for end of life 97 
management than short term health problems.18 In patients with symptomatic spinal metastases, 98 
cost of surgical management over a lifetime horizon has been found to be both more expensive, 99 
and more effective than non-surgical management19,20; the incremental cost per QALY gained 100 
for surgery compared to radiotherapy alone has been estimated at $250,307 by Furlan et al 101 
(2012),19 which is significantly higher than the $50,000 commonly used threshold in the US,21 102 
whilst Miyazaki et al (2017) estimated it at $42,003.22 There is a paucity of data in this area,23 103 
and methodologies differ significantly, giving rise to significant variations in cost effectiveness. 104 
The former study looked at medical costs combined with estimated community palliative care 105 
costs; these high input homecare costs may be reduced by successful surgical intervention, 106 
improving cost effectiveness. 107 
We have studied the cost effectiveness of the surgical treatment of MSCC at one London 108 
center and aimed to determine if reimbursement was broadly in line with cost, and the cost 109 
effectiveness of surgical treatment of metastatic spine disease. 110 
MATERIALS AND METHODS 111 
Subjects 112 
Consecutive patients were prospectively recruited at a single NHS spinal tertiary referral 113 
center in London if they required surgery for symptomatic spinal metastases from any known or 114 
unknown primary cancer, verified by intra-operative histology. Patients were recruited between 115 
2009 and 2015. Patients were included in the analysis if they were confirmed as having died, or 116 
if they had at least 12 months of follow-up data and were confirmed alive in July 2015 following 117 
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a search of records of death, held centrally by Public Health England; those that were alive at 118 
time of analysis were allocated a date of death of July 2015 in order to complete the analysis. 119 
Exclusion criteria were inability to give written informed consent to participate, and age less than 120 
18 years. Informed consent was obtained from all subjects and ethical approval was granted by 121 
the UK National Research Ethics Service. 122 
Outcome measures 123 
Patient demographics, clinical and surgical details were collected during the index 124 
admission. Frankel grade and EQ-5D-3L scores were collected pre-operatively, post-operatively, 125 
at three, six, twelve months and every 12 months thereafter until death. A utility index suitable to 126 
calculating QALYs was calculated from the EQ-5D-3L scores using the UK value set.24 127 
Financial analysis 128 
All costs to the hospital, as described previously,8 as well as tariff reimbursed to the 129 
hospital, including the Market Forces Factor, were extracted from the hospital’s financial 130 
databases for each subject from index admission until death; if still alive, data was collected up 131 
to July 2015. Fifty percent of the cost data was used in our previous report8; the remainder of the 132 
cost data and all the reimbursement data is newly reported here. For each subject, admissions 133 
were retained that included a neurosurgical episode, and a manual search reduced admissions to 134 
those including neurosurgical treatment of symptomatic spinal metastases using electronic 135 
admission details and letters.  136 
Each admission might include more than one finished consultant episode (FCE), for 137 
example, medical oncology and neurosurgery. Although costs can be separated into each FCE, 138 
reimbursement is usually allocated to the FCE carrying the heavier tariff only, for this reason, 139 
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both costs and reimbursements were summed across FCEs for each admission, including critical 140 
care costs, to give a fully absorbed admission cost and admission tariff (reimbursement). 141 
Comparison of cost and reimbursement 142 
All costs and reimbursements were adjusted to 2015/16 financial year using the Personal 143 
Social Services Research Unit (PSSRU) inflation figures.25 Data were analyzed at patient level 144 
by summing admissions, as spinal centers are likely to treat patients for symptomatic spinal 145 
metastases throughout their disease course.  146 
Cost-utility analysis 147 
It is perhaps unethical to repeat a randomized controlled trial (RCT) of surgical treatment 148 
vs. non-surgical management of symptomatic spinal metastases due to the superiority of surgical 149 
management demonstrated in the RCT by Patchell et al (2005)6; as such, it was necessary to 150 
model anticipated reimbursements of a matched, non-surgical, radiotherapy-only cohort, as well 151 
as expected QALYs. This represents the alternative management strategy to surgery. All data 152 
from our subject cohort was initially replicated, to create an identical, model, non-surgical group 153 
to be as close as possible to an RCT-style control arm, with the same baseline as the surgical 154 
group; survival was reduced to 79%, and ambulation to 11% based on the study by Patchell et al 155 
(2005).6 This was considered to be more robust than comparison with a real world subject group 156 
with symptomatic spinal metastases who didn’t undergo surgery, as their baseline characteristics 157 
are unlikely to match those of the surgery group.9,22 158 
It is expected that although the immediate hospital cost of surgically managing 159 
symptomatic spinal metastases is high, surgical intervention may mitigate community costs in 160 
the future by maintaining ambulation for a longer period, and as a result the community costs 161 
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were modeled for both surgical and non-surgical groups using the methods outlined in the MSCC 162 
NICE economic analysis.26 As both hospital reimbursement costs and community care costs 163 
were analyzed, this study had an NHS and social care perspective over a lifetime horizon. 164 
Inpatient reimbursement tariff 165 
Reimbursements, rather than costs, were used for the cost utility analysis, as this analysis 166 
is more pertinent to commissioning at the national level. All tariffs reimbursed were adjusted to 167 
2015/2016 financial year,25 and discounting at 3.5% was applied cumulatively to successive 168 
years in line with current recommendations by NICE.15 Reimbursements for inpatient stays, 169 
including critical care admissions, were then summed to generate total reimbursement per 170 
patient. 171 
Non-surgical management of symptomatic spinal metastases is likely to incorporate radiotherapy 172 
treatment.4 The NICE guidance suggests that this is unlikely to be significantly different to that 173 
received by surgical patients.26 Based on this, radiotherapy costs for the surgical cohort were 174 
analyzed, and the average allocated as an ‘inpatient reimbursement’ to the non-surgical group. 175 
This is expected to be an underestimation of costs as initial diagnostic costs in a medical 176 
oncology episode were not included. 177 
Community care tariff  178 
The NICE MSCC economic analysis sets out a methodology for calculating community 179 
care costs including home care support, community nursing and GP input; these costs are 180 
currently not available for direct analysis at the subject level in the same way as hospital 181 
reimbursements are. Expected costs are based on the PSSRU’s database of community care 182 
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costs,25 inflated to the 2015/2016 financial year, and then discounted following the index year as 183 
with the hospital costs.15 184 
For our surgical group, discharge destinations were known (Table 1). Subjects who did 185 
not go straight home, or to a nursing home were allocated their eventual destination based on 186 
their ability to mobilize at discharge, those that were able to walk (Frankel D or E) were 187 
expected to go home, and those that were unable to walk were expected to be cared for at a 188 
nursing home. In line with NICE guidance, subjects were expected to continue to be cared for at 189 
their discharge location until death.26 190 
Those who went home were allocated a low cost community tariff for the duration of 191 
their ability to walk (£177/week), and a medium cost tariff for the duration that they were unable 192 
to walk (£989/ week). Regardless of which tariff they were on at the end of their lives, a high 193 
cost tariff was allocated for the final two weeks for palliative care (£1481/week). Packages 194 
included increasing levels of social services home care support, as well as increasing levels of 195 
community nursing and GP visits. Those that were cared for at a nursing home were allocated a 196 
single tier tariff for the period of their survival including nursing care costs, accommodation, 197 
ancillary costs and operator profit, regardless of ambulation status (£729/week), (Figure 1).26 198 
For the model non-surgical group, community care costs were initially calculated for both 199 
discharge destination alternatives, as above. For each non-surgical subject, community care cost 200 
was calculated as a percentage of home cost, plus a percentage of a nursing home cost, totaling 201 
100%. This was dependent on their matched subject’s ambulation status at admission (Figure 2). 202 
For both groups, we conducted an additional analysis of community costs using the 2008 203 
NICE figures for home and nursing home healthcare costs, inflated to 2015/2016, as an 204 
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alternative modeling method. This analysis was carried out as a sensitivity analysis to give a 205 
range of possible costs, to make the analysis more robust. 206 
QALYs  207 
In the surgical cohort, QALYs from index admission until death, i.e. the lifetime horizon, 208 
were calculated using the EQ-5D index gathered during follow-up. On death, patients were 209 
allocated an EQ-5D index of zero. QALYs were calculated as the area under the line connecting 210 
EQ-5D index points (Figure 3). Subjects who were still alive in July 2015 were pragmatically 211 
allocated an EQ-5D index of 0 from that point. 212 
In the non-surgical cohort, QALYs were predicted to remain static initially, as any 213 
improvement seen in the surgical group is thought to be related to the surgical intervention. 214 
Given the non-surgical group’s expected shorter ambulation and lifespan, health utility was 215 
modeled as declining from the same time point as the surgical group, with survival being 216 
shortened to 79% as discussed previously (Figure 3).6 217 
Sensitivity analyses were performed to identify if there would have been a significant 218 
change in the results if this method resulted in an under or overestimation of non-surgical 219 
QALYs (Figure 3). Sensitivity analysis one represented that the initial analysis underestimated 220 
QALYs. QALYs were calculated in this scenario as being maintained at pre-operative levels 221 
until the known QALYs from the matched surgical subject became lower than pre-operative 222 
levels, and the non-surgical QALY curve was expected to follow that deterioration, with survival 223 
being reduced to 79% of the surgical subject. Sensitivity analysis two represented that the initial 224 
analysis overestimated QALYs. QALYs were calculated as deteriorating linearly from pre-225 
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operative levels until death at 79% of the surgical patients’ survival. For all QALY calculations, 226 
discounting was applied to all years after the index year at 3.5% as recommended by NICE.15 227 
Statistical analysis  228 
All statistical analysis was carried out in Stata v.12 (Statacorp LP, College Station, TX, 229 
USA). Descriptive details were generated for demographics; financial and QALY data included 230 
medians and IQR because of skewness of the data; means were generated as recommended by 231 
Thompson and Barber (2000)27 and to enable comparison with other studies. The Wilcoxen 232 
signed rank test was used to assess for significant differences in cost and reimbursement, the 233 
spearman correlation coefficient was used to analyze relationships between cost per QALY (the 234 
Incremental Cost Effectiveness Ratio, ICER) and survival time. Significance level was set at 235 
P=.05. 236 
Only subjects with both cost and reimbursement data were used in that comparison 237 
analysis and only those with reimbursement and QALY data were used in the cost-utility 238 
analysis. Where subjects were unavailable for follow-up of EQ-5D-3L scores, the EQ-5D index 239 
was assumed to have improved or deteriorated linearly to the next known point. 240 
RESULTS 241 
During the period of the study, 130 consecutive patients were recruited, of whom 92 had 242 
information available to complete cost and reimbursement comparison, and 100 had information 243 
available to complete the cost utility analysis. 244 
Inpatient cost and reimbursement analysis 245 
In this group, 47 were male (51.1%) and mean age was 60.6 years (SD 14.0). The 246 
majority of patients were not paralyzed at admission (n=64, 69.6%). Median survival was 5.6 247 
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months (IQR 2.5-15.9), mean was 9.8 months (SD 9.6). Of the 22 subjects that were still alive at 248 
analysis (24%), median length of follow-up was 25.0 months (IQR 23.8-36.1), mean was 27.3 249 
months (SD 9.6). 250 
Median cost per surgical patient was £20,752 (IQR £11,550-£30,825; mean £24,445; SD 251 
£17,526), and median reimbursement income received was £18,291 (IQR £17,002-22,089; mean 252 
£21,213; SD £13,163), a median shortfall of £1,967 (IQR shortfall £7,387-saving £5,339) 253 
(Figure 4). Statistical analysis revealed that the difference between cost and reimbursement was 254 
statistically significant (p=.05). 255 
Cost utility analysis 256 
In the surgery group, 49% of subjects were male (n=49), and average age was 59.8 years 257 
(SD 14.2). 69 subjects (69%) were able to walk at admission, and 74 subjects (77%) at discharge 258 
for a median of 13 months (IQR 4.0, 34.0); of those unable to walk at admission, 13 (44.8%) 259 
regained the ability to walk (Table 1 and Figure 5). Median survival was 6.1 months (IQR 2.5, 260 
17.9), mean 10.9 months (SD 11.1); ability to mobilize on discharge had a significant survival 261 
advantage, increasing survival to median 7.7 months (IQR 3.9, 19.0), mean 13.0 (SD 11.8). For 262 
those still alive, median follow-up was 24.9 months (IQR 12.6, 36.1) mean 24.8 (SD 11.8).  263 
After discounting was applied, median reimbursement tariff for hospital admission was 264 
£18,291 (IQR £17,002; 21,768), the mean was £20,950 (SD £12,693), as expected this was 265 
higher than the median due to skewness. For patients undergoing post-operative radiotherapy to 266 
the same spinal level, the mean reimbursement was £6,338, which was applied to the non-267 
surgical group. 268 
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Median community cost was £15,512 for the surgical cohort (IQR £6,440, 29,299), the 269 
mean was £21,955 (SD £21,600). All ambulant patients were cared for at home whilst only 270 
23.8% of non-ambulant patients were cared for at home (Table 1). The median total tariff for this 271 
group was £35,431 (IQR 25,055, 49,701), mean £42,904 (SD £24,768). 272 
Community care tariffs were modeled for the non-surgical group. 69 patients (69%) were 273 
able to walk at admission, and were allocated the home care costs appropriate to their ambulation 274 
length and survival. The remaining patients’ tariff was comprised 23.8% home care tariff, and 275 
76.2% nursing home tariff (Figure 2). The median community tariff was £38,802 (IQR £13,085-276 
83,893; mean £49,404; SD £43,646), and the median total tariff was £45,141 (IQR £19,423, 277 
90,231; mean £55,743; SD £43,646). The median incremental cost difference was £1,107 more 278 
expensive for the surgical group (IQR £38,391 cheaper, £11,702 more expensive), mean £12,839 279 
cheaper for the surgical group (SD £37,896) (Table 2). 280 
The NICE 2008 economic guidance reports that weekly community care tariffs were £91 281 
for an ambulant patient, £1,351 for non-ambulant, £1,918 for a palliative patient and £567 for 282 
patients cared for in nursing homes. When inflated to 2015/2016, this resulted in higher 283 
community care costs, particularly for non-ambulant patients. The total median tariffs using this 284 
approach were £32,002 (IQR £24,357, 42,612; mean £42,819; SD £32,002) for the surgical 285 
group, and £62,854 (IQR £22,846, 112,276; mean £76,958; SD £64,220) for the non-surgical 286 
group. The median incremental cost difference was £7,069 cheaper for the surgical group (IQR 287 
£69,396 cheaper, £10,531 more expensive), mean £34,139 cheaper (SD £63,506) (Table 2). 288 
QALYs were calculated for the surgical group. Health utility scores were available for 99 289 
of 100 subjects at baseline (99%), 60 of 82 subjects alive at three months (73%), 44 of 65 290 
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survivors at six months (68%), 38 of 51 survivors at 12 months (75%), 23 of 28 survivors at 24 291 
months (82%), 8 of 14 survivors at 36 months (57%) and 1 of 3 survivors at 48 months (33%). 292 
Data was missing where patients were unavailable for follow-up, frequently due to deteriorating 293 
health, or where patients were uncontactable. Initial health utility was median 0.33 (0.18, 0.69), 294 
mean 0.41 (SD 0.30). The discounted median QALYs were 0.28 (IQR 0.04-0.99) the mean was 295 
0.64 (SD 0.76). For the non-surgical group they were calculated as median 0.13 (IQR 0.02-0.50), 296 
mean 0.32 (SD 0.41), with a median incremental QALY difference of 0.09 (IQR 0.01, 0.54; 297 
mean 0.32; SD 0.45). The two sensitivity analyses returned QALYs of median 0.17 (IQR 0.02-298 
0.53) and 0.12 (0.02-0.36) respectively with median incremental differences of 0.06 and 0.13, 299 
and mean differences of 0.27 and 0.38 (Figure 3). 300 
Surgery is less costly than no surgery based on the mean, and only marginally more 301 
costly based on the median, it is also the more effective strategy based on the QALY mean and 302 
median, and therefore it must be cost effective as it dominates over no surgery. 303 
The correlations between ambulation time, r=-0.87, or survival time, r=-0.73, and cost 304 
per QALY were significant (P<.01 for both), indicating that it is the mitigation of community 305 
costs which increases the cost effectiveness of surgery in this patient group (Figure 6). 306 
DISCUSSION 307 
Principle findings 308 
Symptomatic spinal metastases represent a significant clinical and economic burden. Our 309 
study is the first in the world to investigate the cost utility of surgical management of 310 
symptomatic spinal metastases using prospectively collected health utility data, and the first 311 
health utility study for MSCC in the UK. There is a perception amongst surgeons that hospitals 312 
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in the UK are under-reimbursed for the work they carry out under the current system; we found a 313 
significant median shortfall of £1,967 between the cost of surgery and the reimbursement to the 314 
hospital. Our results show that over a lifetime horizon, from the NHS and social care perspective, 315 
surgery is less costly and more effective than non-surgical management. This saving is within the 316 
expected threshold set by NICE,15 suggesting surgical management is good value for money, as 317 
well as being clinically effective.6 318 
Strengths and weaknesses of the study 319 
This study has overcome several hurdles of other health economic studies by completing 320 
a prospective study and collecting both cost and health utility data without recourse to searches 321 
by HRG coding. However, inputational models were still required to estimate community care 322 
costs, as this is not currently collected at the patient level, and to estimate QALY and cost data 323 
for a comparative non-surgical cohort. We also recognize that choice of discharge destination is 324 
multi-factorial, but chose this method to replicate the NICE economic analysis.26 A limitation is 325 
that the effect of recent advances in radiotherapy techniques that may prolong ambulation or 326 
survival may be under-represented, one recent study showed 25% of subjects improved with 327 
non-surgical treatment, although there was a mean drop in health utility.22 These limitations were 328 
mitigated where possible by using a conservative estimate of surgical QALYs and non-surgical 329 
costs, and performing sensitivity analyses; censoring data from patients who were alive in July 330 
2015 will have resulted in a conservative estimate of cost per QALY, as cost efficiency is 331 
strongly correlated with survival time (Figure 6). As this was a single center study, it is possible 332 
that some in-hospital costs may have been missed if subjects had further intervention in other 333 
hospital Trusts.  334 
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Comparison to existing literature 335 
The hospital costs of surgical and radiotherapy management are slightly higher than 336 
previously reported by our group (£20,752 vs. £16,885), which is likely to be due the inclusion 337 
of oncology admissions attached to neurosurgical episodes.8 The reimbursement, £18,291, is also 338 
higher than other published material: Body et al (2013)28 reported reimbursement tariffs of 339 
€15.048, and a NICE analysis reported likely costs of £13,094 in 2008,26 these differences are 340 
perhaps due to the different methodologies, and changing time periods of the studies.8,29 341 
A shortfall between cost and reimbursement has been noted in other surgical areas, 342 
including hip and knee revision surgery, which have a shortfall of up to £4,566.12 This was 343 
suggested to be a result of a more complex case mix. However, shortfalls may also be due partly 344 
to variations in hospital efficiency. The reimbursement tariff is created from an average of costs 345 
of admissions for patients undergoing similar procedures across the country, adjusted for market 346 
forces, as costs vary throughout the country. Trusts may also negotiate local changes to the tariff 347 
in some instances. Other specialist centers suggest that they are able to generate lower costs, and 348 
therefore a more beneficial cost: reimbursement ratio, as a result of their frequent management of 349 
a specialist patient group, which is possible in this cohort as it is based at a regional center for 350 
spinal surgery. It is notable that reimbursement is not expected to directly repay each department 351 
pro rata; instead variations are expected across departments, which should balance across a 352 
hospital trust.14 353 
Our calculation showing an overall lifetime saving following surgery in addition to 354 
radiotherapy, from the NHS and social care perspective (i.e. the tariff), is significantly lower than 355 
the only previous estimate using data with a comparable non-surgical group, by Furlan et al 356 
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(2012) of US$250,307 per QALY,19 as well as an estimate using groups with different baseline 357 
characteristics ($42,003 per QALY).22 Whilst in this study the baseline demographic and clinical 358 
measures were similar to those used in Furlan et al.’s study, based on data from Patchell (2005),6 359 
ambulation and survival length, as well as estimated cost methodology are likely to have 360 
contributed to the difference. Median duration of ambulation (152 vs. 122 days) and survival 361 
(185 vs. 126 days) were greater in this report; survival time in more recent studies confirms a 362 
trend to improving survival time following surgical intervention in this patient group.22 The 363 
discrepancy in cost is also likely to be related to the methodology used; this has previously been 364 
reported to be a significant barrier to the comparison of health utility studies.29 The study by 365 
Furlan et al. estimated community care costs based on the cost of palliative care, either at home 366 
or at a nursing home; combined hospital and community costs were estimated as mean $583,809 367 
for a surgical patient and $554,323 for a non-surgical patient.19 The economic guidance by the 368 
National Institute for Health and Clinical Excellence2008) used in this study, suggested that it is 369 
more likely that some patients will require a lower level of support for the majority of their 370 
survival (depending on ambulation status), and only need palliative care in the final weeks of 371 
life; this results in a significant difference in the estimation of community care costs and 372 
therefore cost per QALY26. Our costs of £42,904 for the surgical cohort and £55,743 for the non-373 
surgical cohort are significantly lower, and more closely relate to those of other recent studies; 374 
Tipsmark et al (2015) estimated costs of up to €87,814 and €36,616 for surgical and non-surgical 375 
groups over a lifetime horizon,9 whilst Miyazaki et al (2017) estimated costs of $25,770 and 376 
$8,615 over one year.22 Both studies calculated costs using different methodologies, the first was 377 
based on an insurance register, the second from medical remuneration points. The mitigation of 378 
community care costs as a result of longer survival post-surgery is clearly seen in Figure 6. 379 
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The methodology for generating QALYs was also different in our and Furlan et al.’s study.19 We 380 
collected prospective EQ-5D data throughout the subjects’ life, whereas Furlan et al. created an 381 
estimated health utility generated from interviewing the general population using the time trade-382 
off technique. Furlan et al. used health utilities from the Harvard University Catalogue from the 383 
US and the Health Outcomes Data- health utility list from the UK and multiplied by the period of 384 
time the patient was affected, which would not take into account deterioration during the lifetime 385 
horizon that was demonstrated in our study. Based on a health utility value of 0.388, Furlan et al. 386 
described mean QALYs for radiotherapy only as 0.46 (95% 0.06-3.41), mean QALYS for 387 
surgery and radiotherapy 0.57 (95% 0.13-2.24). The mean initial health utility in our study pre-388 
operatively was 0.41, whilst mean lifetime QALYS were 0.64 for patients undergoing surgery 389 
and 0.32 for patients undergoing radiotherapy only. Miyazaki et al (2017) describe QALYS at 390 
one year as 0.433 for their surgical group; that cohort had a lower health status (0.036) and lower 391 
level of ambulation (54.8%) at baseline than in our study (0.41 and 69% respectively), 392 
furthermore, their patients had tumors with a higher grade of malignancy than in this study, the 393 
first two factors are known predictors of quality of life, and the latter is a prediction of survival 394 
after surgery,7,30 and may account for the lower QALYS gained compared to our study. 395 
Implications for clinicians 396 
Our study has demonstrated a small discrepancy between the cost to the hospital and the 397 
reimbursement from the government for treating this patient group; we have previously reported 398 
that ward cost is the greatest factor in total hospital costs, promoting the implementation of 399 
methods to reduce hospital length of stay. Our result shows that surgery in addition to 400 
radiotherapy is more effective and less expensive than radiotherapy alone over a lifetime 401 
horizon, and despite longer survival, the gain in QALYS following surgery outweighs any costs 402 
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from the longer follow-up, particularly as ambulation is prolonged. The cost per QALY is within 403 
the implied UK threshold for NHS funding,15 supporting managers in commissioning surgical 404 
services for patients with symptomatic spinal metastases.  405 
Future research 406 
Given the significant initial cost outlay in surgical management compared to non-surgical 407 
management, it is vital for cost utility studies in the future to calculate community health care 408 
costs as well as hospital costs, as the mitigation of the community costs at the wider health and 409 
social care level will have a significant impact on the cost per QALY. Ability to directly extract 410 
both health and social care economic data at the patient level will increase the robustness of 411 
future studies.10 412 
CONCLUSION 413 
Our results demonstrate that reimbursement to a tertiary referral hospital for surgical 414 
management of symptomatic spinal metastases in the UK is broadly in line with costs, and that 415 
as a result of community care costs being mitigated by a greater percentage of ambulant patients 416 
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Figure Captions: 512 
Figure 1. Calculation strategy for community care costs for surgical group. 513 
Figure 2. Calculation of community care costs for non-surgical group. 514 
Figure 3. QALY calculations. QALYs were calculated as the area under the curve. Solid line 515 
represents patients treated with surgery, and dashed line is non-surgical series with sensitivity 516 
analyses (dotted lines). 517 
Figure 4. Admission cost and admission income in GBP. The box shows the 25th, 50th and 75th 518 
percentiles, the whiskers encompass values within 1.5 IQR of the closest quartile, outliers are 519 
represented as markers. 520 
Figure 5. Ambulation status of patients over time based on Frankel Score: A-C, not walking; D-521 
E, walking. 522 
Figure 6. Cost per QALY correlation with A: survival, r=-0.73, P<.01 and B: ambulation, r=-523 
0.87, P<.01. 524 
